Compounds > 2,4,3',5'-tetramethoxystilbene
Page last updated: 2024-08-01 17:16:44

2,4,3',5'-tetramethoxystilbene

Description

2,4,3',5'-tetramethoxystilbene: potent inhibitor of human cytochrome P450 1B1; an antihypertensive agent; structure in first source [MeSH]

Cross-References

ID SourceID
PubMed CID5354004
CHEMBL ID46909
SCHEMBL ID4366766
CHEBI ID92804
MeSH IDM0407170

Synonyms (46)

Synonym
BRD-K45988865-001-01-0
TMS ,
2,4,3',5'-tetramethoxystilbene
3,5,2',4'-tetramethoxy-trans-stilbene
2,3',4,5'-tetramethoxystilbene
(e)-2,3',4,5'-tetramethoxystilbene
CHEMBL46909 ,
trans-2,4,3',5'-tetramethoxystilbene
1-[(e)-2-(3,5-dimethoxyphenyl)vinyl]-2,4-dimethoxybenzene
trans-2,4,3'',5''-tetramethoxystilbene
bdbm50108052
1-[(e)-2-(2,4-dimethoxyphenyl)ethenyl]-3,5-dimethoxybenzene
AKOS015967529
20578-92-1
24144-92-1
(e)-1-(3,5-dimethoxystyryl)-2,4-dimethoxybenzene
SCHEMBL4366766
1-[2,(3,5-dimethoxyphenyl)ethenyl]-2,4-dimethoxybenzene
AC-35369
JDBCWSHYEQUBLW-AATRIKPKSA-N
oxyresveratrol tetramethyl ether
HMS3648A21
(e)-4,5'-(ethene-1,2-diyl)bis(1,3-dimethoxybenzene)
trans-2,3',4,5'-tetramethoxystilbene
HY-19340
EX-A1015
SR-01000597603-1
sr-01000597603
CS-5626
CHEBI:92804
AS-71536
1-[(1e)-2-(3,5-dimethoxyphenyl)ethenyl]-2,4-dimethoxybenzene
2,4,3',5'-tetramethoxystilbene, >=98% (hplc)
J-015362
BCP21292
mfcd03428621
HMS3676F17
stilbene, 2,3',4,5'-tetramethoxy-
SR-01000597603-2
HMS3412F17
3,5,2',4'-tetramethoxystilbene
benzene, 1-[(1e)-2-(3,5-dimethoxyphenyl)ethenyl]-2,4-dimethoxy-
A912947
1-[(1e)-2-(3,5-dimethoxyphenyl)ethenyl]-2,4-dimethoxy-benzene
3,5,2 inverted exclamation mark ,4 inverted exclamation mark -tetramethoxystilbene
DTXSID101186212

Protein Targets (4)

Inhibition Measurements

ProteinTaxonomyMeasurementAverage (mM)Bioassay(s)
Cytochrome P450 1A1Homo sapiens (human)IC500.3000AID1453035; AID1533283; AID54202
Cytochrome P450 1A2Homo sapiens (human)IC503.0667AID1453036; AID1533284; AID54221
TyrosinaseHomo sapiens (human)IC50100.0000AID276018
Cytochrome P450 1B1Homo sapiens (human)IC500.0060AID1306443; AID1453034; AID1533285; AID54233
Cytochrome P450 1B1Homo sapiens (human)Ki0.0030AID1533725

Bioassays (21)

Assay IDTitleYearJournalArticle
AID276025Cytotoxicity against human NCI-H187 cells2006Bioorganic & medicinal chemistry letters, Nov-01, Volume: 16, Issue:21
ISSN: 0960-894X		Chemical transformations of oxyresveratrol (trans-2,4,3',5'-tetrahydroxystilbene) into a potent tyrosinase inhibitor and a strong cytotoxic agent.
AID1453034Inhibition of recombinant human CYP1B1 expressed in Escherichia coli DH5alpha using ethoxyresorufin as substrate preincubated for 3 mins followed by NADPH addition measured after 10 mins by spectrofluorometric assay2017European journal of medicinal chemistry, Jul-28, Volume: 135ISSN: 1768-3254Inhibitors of cytochrome P450 (CYP) 1B1.
AID54225Selectivity ratio for Cytochrome P450 1B1 compared to Cytochrome P450 1A22002Journal of medicinal chemistry, Jan-03, Volume: 45, Issue:1
ISSN: 0022-2623		Design, synthesis, and discovery of novel trans-stilbene analogues as potent and selective human cytochrome P450 1B1 inhibitors.
AID276018Inhibition of tyrosinase2006Bioorganic & medicinal chemistry letters, Nov-01, Volume: 16, Issue:21
ISSN: 0960-894X		Chemical transformations of oxyresveratrol (trans-2,4,3',5'-tetrahydroxystilbene) into a potent tyrosinase inhibitor and a strong cytotoxic agent.
AID54233Inhibition of ethoxyresorufin O-deethylation (EROD) in bicistronic bacterial membranes expressing human cytochrome P450 1B12002Journal of medicinal chemistry, Jan-03, Volume: 45, Issue:1
ISSN: 0022-2623		Design, synthesis, and discovery of novel trans-stilbene analogues as potent and selective human cytochrome P450 1B1 inhibitors.
AID1453035Inhibition of recombinant human CYP1A1 expressed in Escherichia coli DH5alpha using ethoxyresorufin as substrate preincubated for 3 mins followed by NADPH addition measured after 10 mins by spectrofluorometric assay2017European journal of medicinal chemistry, Jul-28, Volume: 135ISSN: 1768-3254Inhibitors of cytochrome P450 (CYP) 1B1.
AID1533287Selectivity ratio of IC50 for recombinant human CYP1A1 expressed in Escherichia coli membranes to IC50 for recombinant human CYP1A2 expressed in Escherichia coli membranes2018ACS medicinal chemistry letters, Dec-13, Volume: 9, Issue:12
ISSN: 1948-5875		Adaptable Small Ligand of CYP1 Enzymes for Use in Understanding the Structural Features Determining Isoform Selectivity.
AID54202Inhibition of ethoxyresorufin O-deethylation (EROD) in bicistronic bacterial membranes epressing human cytochrome P450 1A12002Journal of medicinal chemistry, Jan-03, Volume: 45, Issue:1
ISSN: 0022-2623		Design, synthesis, and discovery of novel trans-stilbene analogues as potent and selective human cytochrome P450 1B1 inhibitors.
AID54221Inhibition of ethoxyresorufin O-deethylation (EROD) in bicistronic bacterial membranes expressing human cytochrome P450 1A22002Journal of medicinal chemistry, Jan-03, Volume: 45, Issue:1
ISSN: 0022-2623		Design, synthesis, and discovery of novel trans-stilbene analogues as potent and selective human cytochrome P450 1B1 inhibitors.
AID1533285Inhibition of recombinant human CYP1B1 expressed in Escherichia coli membranes co-expressing NADPH-P450 reductase assessed as reduction in ethoxyresorufin O-de-ethylation preincubated for 3 mins followed by NADPH addition and measured after 10 mins by flu2018ACS medicinal chemistry letters, Dec-13, Volume: 9, Issue:12
ISSN: 1948-5875		Adaptable Small Ligand of CYP1 Enzymes for Use in Understanding the Structural Features Determining Isoform Selectivity.
AID276024Cytotoxicity against human BC cells2006Bioorganic & medicinal chemistry letters, Nov-01, Volume: 16, Issue:21
ISSN: 0960-894X		Chemical transformations of oxyresveratrol (trans-2,4,3',5'-tetrahydroxystilbene) into a potent tyrosinase inhibitor and a strong cytotoxic agent.
AID54204Selectivity ratio for Cytochrome P450 1B1 compared to Cytochrome P450 1A12002Journal of medicinal chemistry, Jan-03, Volume: 45, Issue:1
ISSN: 0022-2623		Design, synthesis, and discovery of novel trans-stilbene analogues as potent and selective human cytochrome P450 1B1 inhibitors.
AID1306443Inhibition of recombinant human CYP1B1 expressed in Escherichia coli DH5aplha cells assessed as O-deethylation of ethoxyresorufin in presence of NADPH measured after 2 mins by spectrofluorometric method2016Bioorganic & medicinal chemistry letters, 07-15, Volume: 26, Issue:14
ISSN: 1464-3405		Aryl morpholino triazenes inhibit cytochrome P450 1A1 and 1B1.
AID1533283Inhibition of recombinant human CYP1A1 expressed in Escherichia coli membranes co-expressing NADPH-P450 reductase assessed as reduction in ethoxyresorufin O-de-ethylation preincubated for 3 mins followed by NADPH addition and measured after 10 mins by flu2018ACS medicinal chemistry letters, Dec-13, Volume: 9, Issue:12
ISSN: 1948-5875		Adaptable Small Ligand of CYP1 Enzymes for Use in Understanding the Structural Features Determining Isoform Selectivity.
AID1533286Selectivity ratio of IC50 for recombinant human CYP1A1 expressed in Escherichia coli membranes to IC50 for recombinant human CYP1B1 expressed in Escherichia coli membranes2018ACS medicinal chemistry letters, Dec-13, Volume: 9, Issue:12
ISSN: 1948-5875		Adaptable Small Ligand of CYP1 Enzymes for Use in Understanding the Structural Features Determining Isoform Selectivity.
AID1533288Selectivity ratio of IC50 for recombinant human CYP1A2 expressed in Escherichia coli membranes to IC50 for recombinant human CYP1B1 expressed in Escherichia coli membranes2018ACS medicinal chemistry letters, Dec-13, Volume: 9, Issue:12
ISSN: 1948-5875		Adaptable Small Ligand of CYP1 Enzymes for Use in Understanding the Structural Features Determining Isoform Selectivity.
AID1533725Inhibition of human CYP1B1 using ethoxyresorufin as substrate preincubated for 3 mins followed by NADPH addition measured after 10 mins by EROD assay2019European journal of medicinal chemistry, Feb-01, Volume: 163ISSN: 1768-3254Phytoestrogens and their synthetic analogues as substrate mimic inhibitors of CYP1B1.
AID1453036Inhibition of recombinant human CYP1A2 expressed in Escherichia coli DH5alpha using ethoxyresorufin as substrate preincubated for 3 mins followed by NADPH addition measured after 10 mins by spectrofluorometric assay2017European journal of medicinal chemistry, Jul-28, Volume: 135ISSN: 1768-3254Inhibitors of cytochrome P450 (CYP) 1B1.
AID1533284Inhibition of recombinant human CYP1A2 expressed in Escherichia coli membranes co-expressing NADPH-P450 reductase assessed as reduction in ethoxyresorufin O-de-ethylation preincubated for 3 mins followed by NADPH addition and measured after 10 mins by flu2018ACS medicinal chemistry letters, Dec-13, Volume: 9, Issue:12
ISSN: 1948-5875		Adaptable Small Ligand of CYP1 Enzymes for Use in Understanding the Structural Features Determining Isoform Selectivity.
AID276017Inhibition of tyrosinase at 100 uM2006Bioorganic & medicinal chemistry letters, Nov-01, Volume: 16, Issue:21
ISSN: 0960-894X		Chemical transformations of oxyresveratrol (trans-2,4,3',5'-tetrahydroxystilbene) into a potent tyrosinase inhibitor and a strong cytotoxic agent.
AID276023Cytotoxicity against human KB cells2006Bioorganic & medicinal chemistry letters, Nov-01, Volume: 16, Issue:21
ISSN: 0960-894X		Chemical transformations of oxyresveratrol (trans-2,4,3',5'-tetrahydroxystilbene) into a potent tyrosinase inhibitor and a strong cytotoxic agent.

Research

Studies (27)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's8 (29.63)29.6817
2010's19 (70.37)24.3611
2020's0 (0.00)2.80

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews2 (7.41%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other25 (92.59%)84.16%
SubstanceStudiesClassesRolesFirst YearLast YearAverage AgeRelationship StrengthTrialspre-19901990's2000's2010'spost-2020
melatonin
1
acetamides;
tryptamines		anticonvulsant;
central nervous system depressant;
geroprotector;
hormone;
human metabolite;
immunological adjuvant;
mouse metabolite;
radical scavenger		201720177.0low000010
4-aminobenzoic acid
1
aminobenzoic acid;
aromatic amino-acid zwitterion		allergen;
Escherichia coli metabolite;
plant metabolite		201620168.0low000010
berberine
2
alkaloid antibiotic;
berberine alkaloid;
botanical anti-fungal agent;
organic heteropentacyclic compound		antilipemic drug;
antineoplastic agent;
antioxidant;
EC 1.1.1.141 [15-hydroxyprostaglandin dehydrogenase (NAD(+))] inhibitor;
EC 1.1.1.21 (aldehyde reductase) inhibitor;
EC 1.13.11.52 (indoleamine 2,3-dioxygenase) inhibitor;
EC 1.21.3.3 (reticuline oxidase) inhibitor;
EC 2.1.1.116 [3'-hydroxy-N-methyl-(S)-coclaurine 4'-O-methyltransferase] inhibitor;
EC 2.1.1.122 [(S)-tetrahydroprotoberberine N-methyltransferase] inhibitor;
EC 2.7.11.10 (IkappaB kinase) inhibitor;
EC 3.1.1.4 (phospholipase A2) inhibitor;
EC 3.1.1.7 (acetylcholinesterase) inhibitor;
EC 3.1.1.8 (cholinesterase) inhibitor;
EC 3.1.3.48 (protein-tyrosine-phosphatase) inhibitor;
EC 3.4.14.5 (dipeptidyl-peptidase IV) inhibitor;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
geroprotector;
hypoglycemic agent;
metabolite;
potassium channel blocker		201720196.0low000020
cannabinol
1
dibenzopyran201720177.0low000010
ellipticine
1
indole alkaloid;
organic heterotetracyclic compound;
organonitrogen heterocyclic compound;
polycyclic heteroarene		antineoplastic agent;
plant metabolite		2006200618.0low000100
emodin
1
trihydroxyanthraquinoneantineoplastic agent;
laxative;
plant metabolite;
tyrosine kinase inhibitor		201720177.0low000010
fluoxetine
1
(trifluoromethyl)benzenes;
aromatic ether;
secondary amino compound		201720177.0low000010
hesperetin
1
ether;
flavonoids		201920195.0medium000010
kojic acid
1
4-pyranones;
enol;
primary alcohol		Aspergillus metabolite;
EC 1.10.3.1 (catechol oxidase) inhibitor;
EC 1.10.3.2 (laccase) inhibitor;
EC 1.13.11.24 (quercetin 2,3-dioxygenase) inhibitor;
EC 1.14.18.1 (tyrosinase) inhibitor;
EC 1.4.3.3 (D-amino-acid oxidase) inhibitor;
NF-kappaB inhibitor;
skin lightening agent		2006200618.0low000100
1,4-phenylenebis(methylene)selenocyanate
1
201720177.0low000010
1,2,5,6-dibenzanthracene
1
ortho-fused polycyclic arenemutagen201720177.0low000010
aniline
1
anilines;
primary arylamine		201620168.0low000010
alizarin
1
dihydroxyanthraquinonechromophore;
dye;
plant metabolite		201720177.0low000010
purpurin
1
trihydroxyanthraquinonebiological pigment;
histological dye;
plant metabolite		201720177.0low000010
4-nitroaniline
1
nitroanilinebacterial xenobiotic metabolite201620168.0low000010
4-bromoaniline
1
201620168.0low000010
morpholine
1
morpholines;
saturated organic heteromonocyclic parent		NMR chemical shift reference compound201620168.0low000010
imperatorin
1
psoralensEC 3.1.1.7 (acetylcholinesterase) inhibitor;
metabolite		201720177.0low000010
flavone
1
flavonesmetabolite;
nematicide		201720177.0low000010
perillyl alcohol
1
limonene monoterpenoidplant metabolite;
volatile oil component		201720177.0low000010
3-hydroxyflavone
1
flavonols;
monohydroxyflavone		201720177.0low000010
alpha-naphthoflavone
2
extended flavonoid;
naphtho-gamma-pyrone;
organic heterotricyclic compound		aryl hydrocarbon receptor agonist;
aryl hydrocarbon receptor antagonist;
EC 1.14.14.14 (aromatase) inhibitor		201720186.5low000020
erythromycin
1
cyclic ketone;
erythromycin		201720177.0low000010
dronabinol
1
benzochromene;
diterpenoid;
phytocannabinoid;
polyketide		cannabinoid receptor agonist;
epitope;
hallucinogen;
metabolite;
non-narcotic analgesic		201720177.0low000010
pyrene
1
ortho- and peri-fused polycyclic arenefluorescent probe;
persistent organic pollutant		201720177.0low000010
rutecarpine
1
beta-carbolines201720177.0low000010
2-methoxyestradiol
1
17beta-hydroxy steroid;
3-hydroxy steroid		angiogenesis modulating agent;
antimitotic;
antineoplastic agent;
human metabolite;
metabolite;
mouse metabolite		201720177.0low000010
isopimpinellin
1
psoralens201720177.0low000010
isoimperatorin
1
psoralensEC 3.1.1.7 (acetylcholinesterase) inhibitor;
metabolite		201720177.0low000010
5-hydroxyflavone
1
flavones201720177.0low000010
4-methoxyestradiol
1
17beta-hydroxy steroid;
3-hydroxy steroid;
aromatic ether;
phenols		estrogen;
human metabolite;
rat metabolite		201720177.0low000010
homoeriodictyol
1
3'-methoxyflavanones;
4'-hydroxyflavanones;
monomethoxyflavanone;
trihydroxyflavanone		flavouring agent;
metabolite		201720177.0low000010
eupatorin
1
dihydroxyflavone;
polyphenol;
trimethoxyflavone		anti-inflammatory agent;
antineoplastic agent;
apoptosis inducer;
Brassica napus metabolite;
calcium channel blocker;
P450 inhibitor;
vasodilator agent		201720177.0low000010
benzyl selenocyanate
1
201720177.0low000010
16-fluoro-5-androsten-17-one
1
201920195.0medium000010
demethyleneberberine
1
201720177.0low000010
resveratrol
3
resveratrolantioxidant;
phytoalexin;
plant metabolite;
quorum sensing inhibitor;
radical scavenger		201620196.7low000030
cannabidiol
1
olefinic compound;
phytocannabinoid;
resorcinols		antimicrobial agent;
plant metabolite		201720177.0low000010
thalifendine
1
201720177.0medium000010
quercetin
2
7-hydroxyflavonol;
pentahydroxyflavone		antibacterial agent;
antineoplastic agent;
antioxidant;
Aurora kinase inhibitor;
chelator;
EC 1.10.99.2 [ribosyldihydronicotinamide dehydrogenase (quinone)] inhibitor;
geroprotector;
phytoestrogen;
plant metabolite;
protein kinase inhibitor;
radical scavenger		201720196.0low000020
biochanin a
1
4'-methoxyisoflavones;
7-hydroxyisoflavones		antineoplastic agent;
EC 3.5.1.99 (fatty acid amide hydrolase) inhibitor;
phytoestrogen;
plant metabolite;
tyrosine kinase inhibitor		201720177.0low000010
formononetin
1
4'-methoxyisoflavones;
7-hydroxyisoflavones		phytoestrogen;
plant metabolite		201720177.0low000010
acacetin
2
dihydroxyflavone;
monomethoxyflavone		anticonvulsant;
plant metabolite		201720196.0low000020
apigenin
2
trihydroxyflavoneantineoplastic agent;
metabolite		201720196.0low000020
luteolin
2
3'-hydroxyflavonoid;
tetrahydroxyflavone		angiogenesis inhibitor;
anti-inflammatory agent;
antineoplastic agent;
apoptosis inducer;
c-Jun N-terminal kinase inhibitor;
EC 2.3.1.85 (fatty acid synthase) inhibitor;
immunomodulator;
nephroprotective agent;
plant metabolite;
radical scavenger;
vascular endothelial growth factor receptor antagonist		201720196.0low000020
chrysoeriol
1
monomethoxyflavone;
trihydroxyflavone		antineoplastic agent;
antioxidant;
metabolite		201720177.0low000010
kaempferol
1
7-hydroxyflavonol;
flavonols;
tetrahydroxyflavone		antibacterial agent;
geroprotector;
human blood serum metabolite;
human urinary metabolite;
human xenobiotic metabolite;
plant metabolite		201920195.0low000010
chrysin
2
7-hydroxyflavonol;
dihydroxyflavone		anti-inflammatory agent;
antineoplastic agent;
antioxidant;
EC 2.7.11.18 (myosin-light-chain kinase) inhibitor;
hepatoprotective agent;
plant metabolite		201720196.0low000020
diosmetin
2
3'-hydroxyflavonoid;
monomethoxyflavone;
trihydroxyflavone		angiogenesis inhibitor;
anti-inflammatory agent;
antineoplastic agent;
antioxidant;
apoptosis inducer;
bone density conservation agent;
cardioprotective agent;
plant metabolite;
tropomyosin-related kinase B receptor agonist;
vasodilator agent		201720196.0low000020
galangin
1
7-hydroxyflavonol;
trihydroxyflavone		antimicrobial agent;
EC 3.1.1.3 (triacylglycerol lipase) inhibitor;
plant metabolite		201720177.0low000010
3-methylquercetin
2
7-hydroxyflavonol;
monomethoxyflavone;
tetrahydroxyflavone		anticoagulant;
EC 1.14.18.1 (tyrosinase) inhibitor;
metabolite		201720196.0low000020
myricetin
1
7-hydroxyflavonol;
hexahydroxyflavone		antineoplastic agent;
antioxidant;
cyclooxygenase 1 inhibitor;
food component;
geroprotector;
hypoglycemic agent;
plant metabolite		201720177.0low000010
trans-2,3',4,5'-tetrahydroxystilbene
3
stilbenoid2002201616.0low000210
pterostilbene
1
diether;
methoxybenzenes;
stilbenol		anti-inflammatory agent;
antineoplastic agent;
antioxidant;
apoptosis inducer;
hypoglycemic agent;
neuroprotective agent;
neurotransmitter;
plant metabolite;
radical scavenger		201720177.0low000010
7-hydroxyflavone
1
hydroxyflavonoid201720177.0low000010
3,3',4,5'-tetramethoxy-trans-stilbene
1
2002200222.0low000100
3,4',5-trimethoxystilbene
1
2002200222.0low000100
bergamottin
1
furanocoumarinmetabolite201720177.0low000010
pinostilbene
1
stilbenol201720177.0low000010
3,5-dihydroxy-4'-methoxystilbene
1
201720177.0low000010
pifithrin-alpha
1
201720177.0high000010
SubstanceStudiesClassesRolesFirst YearLast YearAverage AgeRelationship StrengthTrialspre-19901990's2000's2010'spost-2020
benzo(a)pyrene
1
ortho- and peri-fused polycyclic arenecarcinogenic agent;
mouse metabolite		2011201113.0low000010
ethoxyresorufin
1
phenoxazine2012201212.0low000010
letrozole
1
nitrile;
triazoles		antineoplastic agent;
EC 1.14.14.14 (aromatase) inhibitor		2011201113.0low000010
estrone
1
17-oxo steroid;
3-hydroxy steroid;
phenolic steroid;
phenols		antineoplastic agent;
bone density conservation agent;
estrogen;
human metabolite;
mouse metabolite		2012201212.0low000010
desoxycorticosterone
1
20-oxo steroid;
21-hydroxy steroid;
3-oxo-Delta(4) steroid;
mineralocorticoid;
primary alpha-hydroxy ketone		human metabolite;
mouse metabolite		2010201014.0low000100
alkenes
1
201720177.0low000010
triazoles
1
1,2,3-triazole2011201113.0low000010
16-hydroxyestrone
1
2012201212.0low000010
angiotensin ii
3
amino acid zwitterion;
angiotensin II		human metabolite2010201711.0low000120
resveratrol
1
resveratrolantioxidant;
phytoalexin;
plant metabolite;
quorum sensing inhibitor;
radical scavenger		2001200123.0low000100
eicosapentaenoic acid
1
icosapentaenoic acid;
omega-3 fatty acid		anticholesteremic drug;
antidepressant;
antineoplastic agent;
Daphnia galeata metabolite;
fungal metabolite;
micronutrient;
mouse metabolite;
nutraceutical		201720177.0low000010
stilbenes
21
stilbene2001201913.0medium00010110
rhodamine 123
1
organic cation;
xanthene dye		fluorochrome2008200816.0low000100
trans-2,3',4,5'-tetrahydroxystilbene
1
stilbenoid2010201014.0low000100
20-hydroxy-5,8,11,14-eicosatetraenoic acid
1
HETE;
hydroxy monocarboxylic acid		human metabolite;
mouse metabolite		2010201014.0low000100
12-hydroxy-5,8,10,14-eicosatetraenoic acid
1
2010201014.0low000100
cytochrome c-t
1
2008200816.0low000100
ConditionIndicatedStudiesFirst YearLast YearAverage AgeRelationship StrengthTrialspre-19901990's2000's2010'spost-2020
Anoxemia0
1
2012201212.0low000010
Benign Neoplasms0
1
201920195.0low000010
Blood Pressure, High0
3
2010201412.7low000210
Breast Cancer0
1
2010201014.0low000100
Breast Neoplasms0
1
2010201014.0low000100
Cancer of Colon0
1
201820186.0low000010
Cancer of Prostate0
1
2008200816.0low000100
Cardiac Hypertrophy0
3
2010201711.7low000210
Cardiac Toxicity0
1
201620168.0low000010
Cardiomegaly0
3
2010201711.7low000210
Cardiotoxicity0
1
201620168.0low000010
Chronic Disease0
1
2012201212.0low000010
Chronic Illness0
1
2012201212.0low000010
Cirrhosis0
1
2014201410.0low000010
Colonic Neoplasms0
1
201820186.0low000010
Disease Models, Animal0
1
2010201014.0low000100
Fibrosis0
1
2014201410.0low000010
Hypertension0
3
2010201412.7low000210
Hypertension, Pulmonary0
1
2012201212.0low000010
Hypertension, Renal0
1
2012201212.0low000010
Hypertrophy0
1
2014201410.0low000010
Hypertrophy, Right Ventricular0
1
2012201212.0low000010
Hypoxia0
1
2012201212.0low000010
Inflammation0
2
201220189.0low000020
Innate Inflammatory Response0
2
201220189.0low000020
Kidney Diseases0
1
2014201410.0low000010
Neoplasms0
1
201920195.0low000010
Prostatic Neoplasms0
1
2008200816.0low000100
Proteinuria0
1
2010201014.0low000100
Pulmonary Hypertension0
1
2012201212.0low000010

Safety/Toxicity (1)

ArticleYear
CYP1B1 inhibition attenuates doxorubicin-induced cardiotoxicity through a mid-chain HETEs-dependent mechanism.
Pharmacological research, , Volume: 105		2016

Pharmacokinetics (1)

ArticleYear
Quantification of oxyresveratrol analog trans-2,4,3',5'-tetramethoxystilbene in rat plasma by a rapid HPLC method: application in a pre-clinical pharmacokinetic study.
Biomedical chromatography : BMC, , Volume: 24, Issue:12		2010

Bioavailability (2)

ArticleYear
Tetramethoxystilbene-Loaded Liposomes Restore Reactive-Oxygen-Species-Mediated Attenuation of Dilator Responses in Rat Aortic Vessels Ex vivo.
Molecules (Basel, Switzerland), , Nov-29, Volume: 24, Issue:23		2019
Quantification of oxyresveratrol analog trans-2,4,3',5'-tetramethoxystilbene in rat plasma by a rapid HPLC method: application in a pre-clinical pharmacokinetic study.
Biomedical chromatography : BMC, , Volume: 24, Issue:12		2010

Dosage (1)

ArticleYear
Quantification of oxyresveratrol analog trans-2,4,3',5'-tetramethoxystilbene in rat plasma by a rapid HPLC method: application in a pre-clinical pharmacokinetic study.
Biomedical chromatography : BMC, , Volume: 24, Issue:12		2010